Nivolumab in Recurrent and/or Metastatic SCCHN
NCT03226756
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
351
Enrollment
OTHER
Sponsor class
Conditions
Recurrent and/or Metastatic Platinum-refractory SCCHN
Interventions
DRUG:
Nivolumab Injection
Sponsor
UNICANCER
Collaborators
[object Object]